and the planning was undertaken using Leksell GammaPlan (versions 2.01-5.12). A 1.0-tesla Siemens Expert MR imager was used for treatment planning and for follow-up examinations in all patients. For these studies we used the three-dimensional mpr sequence as described elsewhere. 29 Computerized tomography served as supplementary imaging but was of no consequence to this study.
The GammaPlan software was used for all tumor volumetry. All the measurements were performed by one investigator (B.W.). To assess the variability of the volumetry, a reference tumor was selected and measured repeatedly (10 times) for a period of more than 5 years after GKS with six sequential follow-up intervals.
The dose planning strategy included multiple isocenters with the steepest dose gradient at the anterior margin of the VS (Fig. 1) . Treatment failure was defined as the need for a further therapy if the VS increased significantly in size and if tumor swelling was excluded. For the definition of tumor swelling (mostly transient), a cutoff value of ϩ10% volume increase after GKS was accepted in this study.
Inclusion criteria were the presence of a VS with documented growth or clearly progressive symptoms. The tumor volume was less than 10 cm. 3 All patients attended serial follow-up examinations at the same center where they were treated at regular intervals (3-6, 18-24, and 30-36 months after GKS and then every 2 years). One hundred eleven (63.8%) of the consecutive 174 patients met these criteria and form the basis of the study. All clinical, treatment-related, and all follow-up data (including STV measurements) were stored prospectively in a computerized database. The minimum follow-up period was 5 years. For statistical analysis the StatView program (SAS Institute, Cary, NC) was used.
Results
The results of the volumetry of the reference case are summarized in Table 1 . The percentage standard deviation was 9.3% (range 4.9-13.6%) for all measurements. In the reference case a VS shrinkage of 88% was calculated 6 years after GKS (Fig. 2) . Transient tumor swelling was observed between 3 and 9 months after GKS. At this time interval, the tumor volume increased transiently up to 180% of the treated target volume (Fig. 2) .
Follow-up information was available for 111 patients (100 %) ( Table 2 ). The median follow-up interval was 7 years (range 5-9.6 years). Thirty-seven patients (33%) had undergone surgery before GKS whereas 74 (66.7%) were treated by GKS alone. Ten patients (9%) had NF2. The median VS volume was 1.6 cm 3 (range 0.08-8.7 cm an number of isocenters per patient was eight (range one-25). The median conformity index according to Paddick 39 was 0.68 (range 0.26-1) ( Table 2 ). The median VS shrinkage was 65.5% 4 years after GKS ( Table 3 ). The actuarial 6-year tumor control rate for all patients who had undergone a single GKS treatment was 95%. Ten of 11 recurrent VS were retreated by additional GKS, and one patient underwent microsurgery. Taking into account the retreatments, all tumors were controlled. Recurrence of VS after GKS was associated with NF2 (p Ͻ 0.003) and a lower dose (p Ͻ 0.03) delivered to these tumors ( Fig. 3 and Table 4 ). Tumor swelling was observed in 43 patients (38.7%).
The incidence of facial nerve neuropathy was mainly determined by surgery prior to GKS in that 75% of operated patients were so affected (p Ͻ 0.0001) ( Table 4) . Facial nerve radiation toxicity due to GKS was mild and transient and was observed in three patients with additional risk factors (previous surgery, NF2, and cerebrovascular disease). There was no permanent facial nerve neuropathy after GKS. Trigeminal neuropathy occurred in 13 patients. It was correlated with tumor volume (p Ͻ 0.02). The median hearing loss was Ϫ10 dB (range ϩ20 dB to Ϫ70 dB) as outlined in Table 3 . The risk of hearing loss was correlated with age and transient tumor swelling (p Ͻ 0.05) but not with dose parameters or NF2.
Discussion
The benign natural course of VSs is their prominent feature. In general VSs are not life-threatening tumors. Initially, they cause functional symptoms and compromise the quality of life due to cranial nerve compression or irritation. After longer periods, they may also cause hydrocephalus and brainstem compression. Typically VSs do not grow continuously. There are often longer periods of very slow growth or growth arrest. Even spontaneous regression has been described in 6 to 13% of VS. 4, 17, 51, 55 Therefore, the appropriate time for any therapeutic intervention is a matter of debate. 10 In radiosurgery the treated tumor tissue is left in situ. Different biological mechanisms may account for the modality's final therapeutic result. The induction of apoptosis by GKS has been described, 13, 52 although there may be further reactions involved in the response of VS tissue to GKS. Imaging after GKS, for example, reveals more or less pro- nounced disruption of the interstitial perfusion. 27, 32, 38, 47 The effects of these biological mechanisms may be significant for the clinical and radiological results of GKS.
Traditionally radiosurgical success has been defined as the absence of further tumor growth-that is, tumor stabilization or shrinkage. The response of tumor tissue to GKS, however, is a dynamic process that may hinder the recognition of treatment failures. Several authors have reported increased tumor size after GKS; 24, 32, 38, 40, 56, 58 this swelling is transient in most patients, although it may last for up to 2 years. 32 In the present study, the incidence of transient swelling was found in 39%. Swelling was defined as an increase in tumor volume of 10% or more with respect to the initial tumor volume. This is in line with the findings of other investigators. 58 After the swelling period, most tumors shrink. After 4 years, we measured a volume reduction of 35%. Yu and colleagues 58 reported a similar rate of shrinkage of 46.8% in 92% of their VS cases 30 months after GKS. Thus an overall control rate of 95% was found in our study. These findings are in agreement with other published results. 11, 21, 23, 32, 37, 40, 53, 58 There has been a trend to lower treatment doses for VS during the past decade. 16, 36, 41 In our study a reduced dose level was predominantly applied in patients with NF2 lesions involving the only hearing ear. In these patients an increased recurrence rate was recorded; thus, we urged physicians to be careful when using lower doses. Although radiosurgical retreatment is possible to increase the tumor control rate, according to our experience it is inevitably associated with complete hearing loss.
Sparing facial nerve function is another important issue in VS therapy. In the early days of GKS, the rate of facial nerve dysfunction was 30 to 40%. 37 This rate has been reduced continuously to less than 2%. 11, 21, 53 Our results also support the conclusion of Hudgins 19 that "when patients prefer the preservation of facial nerve function, even if that requires leaving a tumor remnant, then GKS is a better treatment strategy than microsurgical resection." In the current series no patient suffered permanent facial nerve deficit after GKS.
The optimal therapy for hearing preservation remains a matter of debate. No prospective study including surgery, radiosurgery, and fractionated radiotherapy is available. Early GKS has been advocated. 10 Superior results have been claimed for fractionated stereotactic radiotherapy 2,14,44 despite some controversial observations 3, 45 and rather short follow-up periods. The results of microsurgery are difficult to interpret because of inhomogeneous reporting criteria 7 and their dependence on the classification schemes used. 7, 46 On the other hand, progressive hearing loss is found also in nongrowing untreated VS. 15 Thus, the available data in the literature permit the contention that GKS is not associated with an inferior hearing outcome compared with other treatment modalities.
Conclusions
Outpatient GKS is feasible, effective, and safe. Its therapeutic profile compares favorably with that of microsurgery and stereotactic radiation therapy. Tumor volumetry should be a routine part of follow up. 
